173 related articles for article (PubMed ID: 26352467)
1. Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Patel AB; Solomon AR; Mauro MJ; Ehst BD
Dermatology; 2016; 232(1):122-5. PubMed ID: 26352467
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
3. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
4. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
5. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
Moslehi JJ; Deininger M
J Clin Oncol; 2015 Dec; 33(35):4210-8. PubMed ID: 26371140
[TBL] [Abstract][Full Text] [Related]
8. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
[No Abstract] [Full Text] [Related]
9. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
[TBL] [Abstract][Full Text] [Related]
10. Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib.
Nuno-Gonzalez A; Dehesa L; Ricotti C; Kerdel F
Int J Dermatol; 2014 Apr; 53(4):494-6. PubMed ID: 24262013
[No Abstract] [Full Text] [Related]
11. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
[TBL] [Abstract][Full Text] [Related]
13. Cancer-drug discovery and cardiovascular surveillance.
Groarke JD; Cheng S; Moslehi J
N Engl J Med; 2013 Nov; 369(19):1779-81. PubMed ID: 24180496
[No Abstract] [Full Text] [Related]
14. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
15. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Jain P; Kantarjian H; Boddu PC; Nogueras-González GM; Verstovsek S; Garcia-Manero G; Borthakur G; Sasaki K; Kadia TM; Sam P; Ahaneku H; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Cortes JE
Blood Adv; 2019 Mar; 3(6):851-861. PubMed ID: 30885996
[TBL] [Abstract][Full Text] [Related]
16. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
17. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Brouard MC; Prins C; Mach-Pascual S; Saurat JH
Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
Barber MC; Mauro MJ; Moslehi J
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):110-114. PubMed ID: 29222244
[TBL] [Abstract][Full Text] [Related]
20. Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia.
Fiets RB; Staal AHJ; Cramer GE; Blijlevens NMA
Neth J Med; 2018 Sep; 76(7):330-335. PubMed ID: 30220658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
